Table 2 Intervention studies reporting plasma or serum peroxidation biomarkers and Total Antioxidant Capacity in psoriasis: association with inflammation and lipid profile

[33]

7: topical treatment^a

↑

Single application

[28]

67: topical treatment^b

↓ TBARS

20 days

[57]

67: topical treatment^b

↓ TBARS

20 days

[26]

10: topical treatment^c

↓ TBARS

↔

↔ CRP

↔ CHOL, LDL, HDL, TG

↔ oxLDL

11: NB UVB

↔ TBARS, oxLDL

↔

↓ CRP

↔ CHOL, LDL, HDL, TG

13: PUVA

↔ TBARS, oxLDL

↓

↓ CRP

↔ CHOL, LDL, HDL, TG

3, 6, and 12 weeks (3 treatments in parallel)

[27]

10: topical treatment^c

↓ TBARS

↔

↔ CRP

17: NB UVB

↓ TBARS

↔

↓ CRP

20: PUVA

↓ TBARS

↔

↓ CRP

3, 6, and 12 weeks (2 treatments in parallel)

[39]

32: BB UVB

↑ TBARS

21 weeks (longitudinal)

[59]

24: NB UVB

↑ TOS

↔

↔ CRP

30 sessions (longitudinal)

[60]

3: MMF

↔ MDA

↔ CRP

1 months (longitudinal)

[29]

58: MTX

↑ MDA

↔

6 and 12 weeks (longitudinal)

[61]

26: MTX

↔ TOS

↔

↓ CHOL, LDL, HDL

8 weeks (longitudinal)

[21]

13: Infliximab

↓ MDA

↔

↓ ROS

6 months (parallel: treated versus 16 untreated patients)

[62]

23: Etanercept

↓ peroxides

↑

↓ CRP

↔ CHOL, LDL, HDL, TG

24 weeks (longitudinal)

[44]

24: Efalizumab

↓ MDA

↔ IL-8

12-week (longitudinal)

↓ Ex-vivo TNF-α and IFN-γ